STOCK TITAN

[8-K/A] Kintara Therapeutics, Inc. Common Stock Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A

TuHURA Biosciences completed the acquisition of Kineta, Inc. on June 30, 2025 under the Agreement and Plan of Merger dated December 11, 2024, as amended May 5, 2025. The transaction was structured as a two-step series of mergers: Merger Sub I merged into Kineta (the Surviving Entity), which then merged into Merger Sub II, with Merger Sub II surviving.

This Form 8-K/A amends TuHURA’s original June 30, 2025 report to furnish Item 9.01 financial disclosures. The amendment attaches Kineta’s unaudited consolidated financial statements as of March 31, 2025 and December 31, 2024 as Exhibit 99.1 and provides unaudited pro forma condensed combined financial information for TuHURA as Exhibit 99.2, including a pro forma balance sheet and statements of operations on the noted dates and periods. The filing notes substantially the same financial statements were previously included in TuHURA’s Form S-4, declared effective May 14, 2025. The amendment is signed by CFO Dan Dearborn.

TuHURA Biosciences ha completato l'acquisizione di Kineta, Inc. il 30 giugno 2025 ai sensi dell'Agreement and Plan of Merger datato 11 dicembre 2024, emendato il 5 maggio 2025. L'operazione è stata strutturata come una serie di fusioni in due fasi: Merger Sub I si è fusa in Kineta (l'entità sopravvissuta), che successivamente si è fusa in Merger Sub II, con la sopravvivenza di Merger Sub II.

Questo Form 8-K/A modifica il rapporto originario di TuHURA del 30 giugno 2025 per fornire le divulgazioni finanziarie richieste dalla voce 9.01. L'emendamento allega i bilanci consolidati non certificati di Kineta al 31 marzo 2025 e al 31 dicembre 2024 come Exhibit 99.1 e presenta informazioni finanziarie combinate condensate pro forma non certificate per TuHURA come Exhibit 99.2, inclusi uno stato patrimoniale pro forma e i conti economici per le date e i periodi indicati. Il documento precisa che sostanzialmente gli stessi bilanci erano già stati inclusi nel Form S-4 di TuHURA, dichiarato efficace il 14 maggio 2025. L'emendamento è firmato dal CFO Dan Dearborn.

TuHURA Biosciences completó la adquisición de Kineta, Inc. el 30 de junio de 2025 conforme al Agreement and Plan of Merger fechado el 11 de diciembre de 2024, enmendado el 5 de mayo de 2025. La transacción se estructuró como una serie de fusiones en dos pasos: Merger Sub I se fusionó con Kineta (la entidad sobreviviente), que luego se fusionó con Merger Sub II, permaneciendo Merger Sub II como la entidad superviviente.

Este Form 8-K/A enmienda el informe original de TuHURA del 30 de junio de 2025 para proporcionar las divulgaciones financieras del ítem 9.01. La enmienda adjunta los estados financieros consolidados no auditados de Kineta al 31 de marzo de 2025 y al 31 de diciembre de 2024 como Exhibit 99.1 y proporciona información financiera combinada pro forma condensada no auditada para TuHURA como Exhibit 99.2, incluidos un balance pro forma y estados de resultados para las fechas y períodos indicados. El documento señala que, en esencia, los mismos estados financieros ya se habían incluido en el Form S-4 de TuHURA, declarado efectivo el 14 de mayo de 2025. La enmienda está firmada por el CFO Dan Dearborn.

TuHURA Biosciences는 2025년 6월 30일 Kineta, Inc.의 인수를 완료했습니다 — 해당 거래는 2024년 12월 11일자 Agreement and Plan of Merger(2025년 5월 5일 수정)를 근거로 합니다. 거래는 두 단계의 합병으로 구성되었으며, Merger Sub I가 Kineta(존속 법인)와 합병한 뒤 Kineta가 Merger Sub II와 합병하여 Merger Sub II가 존속 법인이 되었습니다.

이 Form 8-K/A는 TuHURA의 2025년 6월 30일자 원래 보고서를 수정하여 항목 9.01에 따른 재무 공시를 제공하는 것입니다. 이 수정서에는 Kineta의 미감사 연결재무제표(2025년 3월 31일 및 2024년 12월 31일 기준)가 Exhibit 99.1로 첨부되어 있으며, TuHURA에 대한 미감사 프로포마 요약 결합 재무정보(지정된 날짜 및 기간의 프로포마 대차대조표 및 손익계산서 포함)가 Exhibit 99.2로 제공됩니다. 제출서에는 본질적으로 동일한 재무제표가 2025년 5월 14일 효력을 발생한 TuHURA의 Form S-4에 이미 포함되어 있었다고 기재되어 있습니다. 이 수정서는 CFO Dan Dearborn의 서명으로 제출되었습니다.

TuHURA Biosciences a finalisé l'acquisition de Kineta, Inc. le 30 juin 2025 en vertu de l'Agreement and Plan of Merger daté du 11 décembre 2024, amendé le 5 mai 2025. La transaction a été structurée en deux étapes de fusions : Merger Sub I a fusionné avec Kineta (l'entité survivante), qui a ensuite fusionné avec Merger Sub II, Merger Sub II demeurant l'entité survivante.

Ce Form 8-K/A modifie le rapport initial de TuHURA en date du 30 juin 2025 afin de fournir les divulgations financières requises à l'item 9.01. L'amendement joint les états financiers consolidés non audités de Kineta au 31 mars 2025 et au 31 décembre 2024 en tant qu'Exhibit 99.1 et fournit des informations financières combinées condensées pro forma non auditées pour TuHURA en tant qu'Exhibit 99.2, incluant un bilan pro forma et des comptes de résultat pour les dates et périodes indiquées. Le dépôt précise que ces mêmes états financiers figuraient essentiellement déjà dans le Form S-4 de TuHURA, déclaré efficace le 14 mai 2025. L'amendement est signé par le CFO Dan Dearborn.

TuHURA Biosciences hat die Übernahme von Kineta, Inc. am 30. Juni 2025 abgeschlossen gemäß dem Agreement and Plan of Merger vom 11. Dezember 2024, geändert am 5. Mai 2025. Die Transaktion wurde als zweistufige Reihe von Fusionen strukturiert: Merger Sub I fusionierte mit Kineta (der überlebenden Einheit), die anschließend mit Merger Sub II verschmolz, wobei Merger Sub II als überlebende Einheit verbleibt.

Dieses Form 8-K/A ändert TuHURAs ursprünglichen Bericht vom 30. Juni 2025, um die finanziellen Angaben nach Punkt 9.01 bereitzustellen. Die Änderung fügt Kinetas ungeprüfte konsolidierte Abschlüsse zum 31. März 2025 und zum 31. Dezember 2024 als Exhibit 99.1 bei und stellt ungeprüfte pro forma verdichtete kombinierte Finanzinformationen für TuHURA als Exhibit 99.2 bereit, einschließlich einer pro forma Bilanz und Gewinn- und Verlustrechnungen für die angegebenen Daten und Zeiträume. Die Einreichung weist darauf hin, dass im Wesentlichen dieselben Abschlüsse bereits im TuHURA Form S-4 enthalten waren, das am 14. Mai 2025 in Kraft trat. Die Änderung ist vom CFO Dan Dearborn unterzeichnet.

Positive
  • Acquisition completed: TuHURA completed the mergers to acquire Kineta on June 30, 2025 under the amended Merger Agreement dated Dec 11, 2024 (amended May 5, 2025).
  • Target financials provided: Unaudited consolidated financial statements of Kineta as of March 31, 2025 and December 31, 2024 are attached as Exhibit 99.1.
  • Pro forma information filed: Unaudited pro forma condensed combined balance sheet and statements of operations for TuHURA are attached as Exhibit 99.2, including notes to pro forma statements.
  • Prior disclosures referenced: Substantially the same financial statements were included in TuHURA’s Form S-4, declared effective May 14, 2025, supporting consistency of disclosures.
Negative
  • None.

Insights

TL;DR: TuHURA closed the Kineta acquisition and has filed the target's unaudited financials plus pro forma combined statements for investor review.

This amendment supplies the financial exhibits investors need to assess the transaction: Kineta's unaudited consolidated statements and pro forma condensed combined financial information for TuHURA. The filing confirms prior S-4 disclosure (declared effective May 14, 2025), reducing disclosure gaps and enabling analysis of pro forma balance and operating results as if the Transactions and earlier reverse merger were consummated on the pro forma dates.

Impact assessment: Impactful for transparency; rating: 0 (neutral) because the amendment provides required information but does not by itself change operating results.

TL;DR: The two-step merger closed June 30, 2025; this 8-K/A supplies Item 9.01 exhibits (Exhibits 99.1 and 99.2) required after closing.

The described structure—a first merger leaving Kineta as the surviving entity followed by a second merger into Merger Sub II—is a common reverse triangular sequence for stock-for-stock or statutory combination transactions. Filing the acquired company's interim and historical unaudited statements and the pro forma combined financials is standard post-closing compliance, helping stakeholders verify accounting consolidation and pro forma adjustments tied to the Transactions and the earlier Kintara reverse merger.

Impact assessment: Impactful from a disclosure and compliance perspective; rating: 0 (neutral) since the documents provide transparency but do not assert financial performance changes beyond the pro forma presentation.

TuHURA Biosciences ha completato l'acquisizione di Kineta, Inc. il 30 giugno 2025 ai sensi dell'Agreement and Plan of Merger datato 11 dicembre 2024, emendato il 5 maggio 2025. L'operazione è stata strutturata come una serie di fusioni in due fasi: Merger Sub I si è fusa in Kineta (l'entità sopravvissuta), che successivamente si è fusa in Merger Sub II, con la sopravvivenza di Merger Sub II.

Questo Form 8-K/A modifica il rapporto originario di TuHURA del 30 giugno 2025 per fornire le divulgazioni finanziarie richieste dalla voce 9.01. L'emendamento allega i bilanci consolidati non certificati di Kineta al 31 marzo 2025 e al 31 dicembre 2024 come Exhibit 99.1 e presenta informazioni finanziarie combinate condensate pro forma non certificate per TuHURA come Exhibit 99.2, inclusi uno stato patrimoniale pro forma e i conti economici per le date e i periodi indicati. Il documento precisa che sostanzialmente gli stessi bilanci erano già stati inclusi nel Form S-4 di TuHURA, dichiarato efficace il 14 maggio 2025. L'emendamento è firmato dal CFO Dan Dearborn.

TuHURA Biosciences completó la adquisición de Kineta, Inc. el 30 de junio de 2025 conforme al Agreement and Plan of Merger fechado el 11 de diciembre de 2024, enmendado el 5 de mayo de 2025. La transacción se estructuró como una serie de fusiones en dos pasos: Merger Sub I se fusionó con Kineta (la entidad sobreviviente), que luego se fusionó con Merger Sub II, permaneciendo Merger Sub II como la entidad superviviente.

Este Form 8-K/A enmienda el informe original de TuHURA del 30 de junio de 2025 para proporcionar las divulgaciones financieras del ítem 9.01. La enmienda adjunta los estados financieros consolidados no auditados de Kineta al 31 de marzo de 2025 y al 31 de diciembre de 2024 como Exhibit 99.1 y proporciona información financiera combinada pro forma condensada no auditada para TuHURA como Exhibit 99.2, incluidos un balance pro forma y estados de resultados para las fechas y períodos indicados. El documento señala que, en esencia, los mismos estados financieros ya se habían incluido en el Form S-4 de TuHURA, declarado efectivo el 14 de mayo de 2025. La enmienda está firmada por el CFO Dan Dearborn.

TuHURA Biosciences는 2025년 6월 30일 Kineta, Inc.의 인수를 완료했습니다 — 해당 거래는 2024년 12월 11일자 Agreement and Plan of Merger(2025년 5월 5일 수정)를 근거로 합니다. 거래는 두 단계의 합병으로 구성되었으며, Merger Sub I가 Kineta(존속 법인)와 합병한 뒤 Kineta가 Merger Sub II와 합병하여 Merger Sub II가 존속 법인이 되었습니다.

이 Form 8-K/A는 TuHURA의 2025년 6월 30일자 원래 보고서를 수정하여 항목 9.01에 따른 재무 공시를 제공하는 것입니다. 이 수정서에는 Kineta의 미감사 연결재무제표(2025년 3월 31일 및 2024년 12월 31일 기준)가 Exhibit 99.1로 첨부되어 있으며, TuHURA에 대한 미감사 프로포마 요약 결합 재무정보(지정된 날짜 및 기간의 프로포마 대차대조표 및 손익계산서 포함)가 Exhibit 99.2로 제공됩니다. 제출서에는 본질적으로 동일한 재무제표가 2025년 5월 14일 효력을 발생한 TuHURA의 Form S-4에 이미 포함되어 있었다고 기재되어 있습니다. 이 수정서는 CFO Dan Dearborn의 서명으로 제출되었습니다.

TuHURA Biosciences a finalisé l'acquisition de Kineta, Inc. le 30 juin 2025 en vertu de l'Agreement and Plan of Merger daté du 11 décembre 2024, amendé le 5 mai 2025. La transaction a été structurée en deux étapes de fusions : Merger Sub I a fusionné avec Kineta (l'entité survivante), qui a ensuite fusionné avec Merger Sub II, Merger Sub II demeurant l'entité survivante.

Ce Form 8-K/A modifie le rapport initial de TuHURA en date du 30 juin 2025 afin de fournir les divulgations financières requises à l'item 9.01. L'amendement joint les états financiers consolidés non audités de Kineta au 31 mars 2025 et au 31 décembre 2024 en tant qu'Exhibit 99.1 et fournit des informations financières combinées condensées pro forma non auditées pour TuHURA en tant qu'Exhibit 99.2, incluant un bilan pro forma et des comptes de résultat pour les dates et périodes indiquées. Le dépôt précise que ces mêmes états financiers figuraient essentiellement déjà dans le Form S-4 de TuHURA, déclaré efficace le 14 mai 2025. L'amendement est signé par le CFO Dan Dearborn.

TuHURA Biosciences hat die Übernahme von Kineta, Inc. am 30. Juni 2025 abgeschlossen gemäß dem Agreement and Plan of Merger vom 11. Dezember 2024, geändert am 5. Mai 2025. Die Transaktion wurde als zweistufige Reihe von Fusionen strukturiert: Merger Sub I fusionierte mit Kineta (der überlebenden Einheit), die anschließend mit Merger Sub II verschmolz, wobei Merger Sub II als überlebende Einheit verbleibt.

Dieses Form 8-K/A ändert TuHURAs ursprünglichen Bericht vom 30. Juni 2025, um die finanziellen Angaben nach Punkt 9.01 bereitzustellen. Die Änderung fügt Kinetas ungeprüfte konsolidierte Abschlüsse zum 31. März 2025 und zum 31. Dezember 2024 als Exhibit 99.1 bei und stellt ungeprüfte pro forma verdichtete kombinierte Finanzinformationen für TuHURA als Exhibit 99.2 bereit, einschließlich einer pro forma Bilanz und Gewinn- und Verlustrechnungen für die angegebenen Daten und Zeiträume. Die Einreichung weist darauf hin, dass im Wesentlichen dieselben Abschlüsse bereits im TuHURA Form S-4 enthalten waren, das am 14. Mai 2025 in Kraft trat. Die Änderung ist vom CFO Dan Dearborn unterzeichnet.

TuHURA Biosciences, Inc./NV NASDAQ true 0001498382 0001498382 2025-06-30 2025-06-30
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

 

Amendment No. 1

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2025

 

 

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Nevada   001-37823   99-0360497
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

10500 University Center Dr., Suite 110

Tampa, Florida 33612

(Address of Principal Executive Offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 


Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 par value per share   HURA   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Explanatory Note

On June 30, 2025, TuHURA Biosciences, Inc., a Nevada corporation (“TuHURA”), completed the previously announced acquisition contemplated by the Agreement and Plan of Merger, dated December 11, 2024, as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the “Merger Agreement”), by and among TuHURA, Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (“Merger Sub I”), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA (“Merger Sub II”), Kineta, Inc., a Delaware corporation (“Kineta”), and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta. Pursuant to the terms of the Merger Agreement, among other things, (a) Merger Sub I merged with and into Kineta (the “First Merger”), with Kineta being the surviving corporation of the First Merger, also known as the “Surviving Entity” and (b) immediately following the First Merger, the Surviving Entity merged with and into Merger Sub II (the “Second Merger”, and together with the First Merger, the “Mergers”), with Merger Sub II being the surviving company of the Second Merger.

TuHURA filed a Current Report on Form 8-K in connection with the Mergers on June 30, 2025 (the “Original Report”). This Current Report on Form 8-K/A (this “Amendment”) amends the Original Report to amend and supplement Item 9.01 of the Original Report. Except as provided herein, the disclosures made in the Original Report remain unchanged.

 

Item 9.01.

Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired

 

   

Pursuant to General Instruction B.3 of Form 8-K, the consolidated balance sheets of the acquired company, Kineta, as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years ended December 31, 2024 and 2023, and the related notes, are not required in the Original Report, as amended by this Amendment, because “substantially the same” financial statements were previously filed in TuHURA’s Registration Statement on Form S-4 (File No. 333-284787), initially filed on February 7, 2025, as amended, and declared effective by the Securities Exchange Commission on May 14, 2025.

 

   

The unaudited consolidated balance sheets of Kineta as of March 31, 2025 and December 31, 2024, and the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the three months ended March 31, 2025 and 2024, and the related notes, are attached as Exhibit 99.1 to this Amendment and incorporated by reference herein.


(b) Pro forma financial information.

The following unaudited pro forma financial information of TuHURA is attached as Exhibit 99.2 to this Amendment and incorporated by reference herein:

 

   

Unaudited Pro Forma Condensed Combined Balance Sheet for TuHURA as of March 31, 2025, on a pro forma basis as if the Mergers and TuHURA’s previously announced reverse merger with Kintara Therapeutics, Inc. that closed on October 18, 2024 (the “Kintara Merger”, and together with the Mergers, the “Transactions”) had been consummated on March 31, 2025.

 

   

Unaudited Pro Forma Condensed Combined Statements of Operations for TuHURA for the three months ended March 31, 2025, on a pro forma basis as if the Transactions had been consummated on March 31, 2025.

 

   

Unaudited Pro Forma Condensed Combined Statement of Operations for TuHURA for the year ended December 31, 2024, on a pro forma basis as if the Transactions had been consummated on January 1, 2024.

 

   

Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements.

(d) Exhibits.

The following documents are filed herewith as exhibits to this Amendment:

 

Exhibit
No.
  

Description

99.1    Unaudited Consolidated Financial Statements of Kineta, Inc. as of and for the three months ended March 31, 2025
99.2    Unaudited Pro Forma Condensed Combined Financial Information of TuHURA Biosciences, Inc. as of and for the three months ended March 31, 2025 and for the year ended December 31, 2024
104    Cover page interactive data file (embedded within the inline XBRL document


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      TUHURA BIOSCIENCES, INC.
Date: August 12, 2025     By:  

/s/ Dan Dearborn

    Name:   Dan Dearborn
    Title:   Chief Financial Officer

FAQ

When did TuHURA complete the acquisition of Kineta?

TuHURA completed the acquisition of Kineta on June 30, 2025 pursuant to the Merger Agreement dated December 11, 2024, as amended May 5, 2025.

What financial exhibits were added by this Form 8-K/A?

The amendment attaches Kineta’s unaudited consolidated financial statements as of March 31, 2025 and December 31, 2024 as Exhibit 99.1, and unaudited pro forma condensed combined financial information for TuHURA as Exhibit 99.2.

Were these financial statements previously filed elsewhere?

Yes. The filing states that substantially the same financial statements were previously filed in TuHURA’s Registration Statement on Form S-4 (File No. 333-284787), initially filed February 7, 2025 and declared effective May 14, 2025.

What pro forma periods are included in the amendment?

Exhibit 99.2 includes a pro forma condensed combined balance sheet as of March 31, 2025, pro forma statements of operations for the three months ended March 31, 2025, and a pro forma statement of operations for the year ended December 31, 2024.

Who signed the Form 8-K/A for TuHURA?

The amendment is signed by Dan Dearborn, Chief Financial Officer, with the signature date shown as August 12, 2025.
Kintara Therapeutics, Inc.

NASDAQ:KTRA

KTRA Rankings

KTRA Latest News

KTRA Latest SEC Filings

KTRA Stock Data

11.99M
55.66M
Polish and Other Sanitation Good Manufacturing
Pharmaceutical Preparations
Link
US
SAN DIEGO